SLC5A2 and Hypoglycemia: However, with the application of Glucagon-likepeptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors,patients may not need to bear the risk of hypoglycemia and could benefit fromtheir cardiovascular protection [33].